Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Clinical trial NCT06784648 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06784648
Sponsor: BioInvent International AB
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Melanoma Metastatic Melanoma of Skin Melanoma BRAF V600E/K Mutated Melanoma Recurrent Melanoma Stage III or IV Melanoma Melanoma Negative for bRAF Melanoma Negative for nRAS Melanomas Uveal Melanoma, Metastatic

Start date: 2024-12-11
Primary completion: 2025-12-30
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.